Medical Treatment & Prevention

Description

No matching items found.

People

  

  

  

1 of 8

  

  

  

• ALUCK THIPAYARAT
• BOONSERM KAEWKAMNERDPONG
• CHANYAPORN BSTIELER
• DUANGHATHAI WIWATRATANA
• DUJDUAN WARAHO

Publications

  

  

  

11 of 17

  

  

  

• ● Interpretable prediction of drug synergy for breast cancer by random forest with features from Boolean modeling of signaling pathways; Taoma K.; Ruengjitchatchawalya M.; Kusonmano K.; Termsaithong T.; Sutthibutpong T.; Liangruksa M.; Laomettachit T.; 2025; Journal article
• ● Interpreting drug synergy in breast cancer with deep learning using target-protein inhibition profiles; Srithanyarat, Thanyawee; Taoma, Kittisak; Sutthibutpong, et al.; 2024; Journal article
• ● Investigating pharmacokinetic profiles of Centella asiatica using machine learning and PBPK modelling; Siriwan Pumkathin, Yuranan Hanlumyuang, Worawat Wattanathana, et al.; 2024; Journal article
• ● Isolation of PCSK9-specific nanobodies from synthetic libraries using a combined protein selection strategy; ApisittThaiprayoon, Yodpong Chantarasorn, Worrapoj Oonanant, et al.; 2025; Journal article
• ● Mathematical Model for the Spread of COVID-19; Tanaporn Jantong, Warissara Wangpia, Prapanporn Rattana, et al.; 2022; Conference proceedings article

Projects

  

  

  

1 of 3

  

  

  

• ● Characterizing tissue biomechanical properties for development of artificial tissue; TEERANOOT CHANTHASOPEEPHAN - Department of Mechanical Engineering
• ● Cosmeceutical mask sheet for skin care whitening and antiaging agent using innovative cellulose acetate electrospun fibers doped with a natural oxyresveratal ; NAKORN NIAMNONT - Department of Chemistry
• ● Development of a phototriggerable liposomal delivery system for emblica fruit extract for the treatment of psoriasis; KWANCHANOK PASUWAT - Department of Chemical Engineering
• ● Development of nanobodies specific to the CHRD domain of proprotein convertase subtilisin/kexin type 9 (PCSK9) as biologics for treatment of high blood LDL-cholesterol level; DUJDUAN WARAHO - Faculty of Engineering
• ● Development of nanobody specific to receptor binding domain of SARS-CoV-2 for applying as antibody drug for COVID-19 treatment; DUJDUAN WARAHO - Faculty of Engineering